Effects of raloxifene on the renin–angiotensin–aldosterone system and blood pressure in hypertensive and normotensive osteoporotic postmenopausal women
Article first published online: 8 OCT 2009
© 2009 Japan Geriatrics Society
Geriatrics & Gerontology International
Volume 10, Issue 1, pages 70–77, January 2010
How to Cite
Sumino, H., Ichikawa, S., Kasama, S., Takahashi, T., Kumakura, H., Takayama, Y., Kanda, T., Murakami, M. and Kurabayashi, M. (2010), Effects of raloxifene on the renin–angiotensin–aldosterone system and blood pressure in hypertensive and normotensive osteoporotic postmenopausal women. Geriatrics & Gerontology International, 10: 70–77. doi: 10.1111/j.1447-0594.2009.00562.x
- Issue published online: 21 DEC 2009
- Article first published online: 8 OCT 2009
- Accepted for publication 20 August 2009.
- blood pressure;
- postmenopausal women;
- renin–angiotensin–aldosterone system
Aim: An increase in blood pressure after menopause has been documented. The renin–angiotensin–aldosterone system (RAAS) plays a central role in the regulation of blood pressure and in the pathophysiology of hypertension. This study investigated the effects of raloxifene, a selective estrogen receptor modulator, on components of the RAAS and blood pressure in hypertensive and normotensive osteoporotic postmenopausal women.
Methods: A total of 41 hypertensive or normotensive postmenopausal women with osteoporosis or osteopenia were divided into four groups. Eleven hypertensive and eight normotensive women received raloxifene hydrochloride (60 mg/day) p.o. for 6 months, and 12 hypertensive and 10 normotensive women did not receive raloxifene hydrochloride for 6 months. In all of the hypertensive women, blood pressure had been controlled prior to the start of the study using a variety of antihypertensive drugs other than angiotensin-converting enzyme (ACE) inhibitors, angiotensin (Ang)II type 1 receptor antagonists or diuretics. Plasma renin activity (PRA), serum ACE activity, plasma AngI, AngII and aldosterone concentrations, and blood pressure were measured before and 6 months after the start of the study.
Results: No significant changes in PRA, ACE activity, or the AngI, AngII or aldosterone levels were observed in any of the groups. In all the groups, blood pressure remained unchanged.
Conclusion: Raloxifene may have no significant effect on the RAAS or blood pressure in hypertensive and normotensive osteoporotic postmenopausal women.